Mesenchymal stem cells (MSCs) are known for being multi-potent. However, they also
possess anticancer properties, which has prompted efforts to adapt MSCs for anticancer …

Leukemia is an aggressive hematologic neoplastic disease. Therapy-resistant leukemic
stem cells (LSCs) may contribute to the relapse of the disease. LSCs are thought to be …

The outcome for pediatric acute lymphoblastic leukemia (ALL) patients who relapse is
dismal. A hallmark of relapsed disease is acquired resistance to multiple chemotherapeutic …

Mesenchymal stem cells (MSCs) exert a tumor-promoting effect in a variety of human
cancers. This study was designed to identify the molecular mechanisms related to the tumor …

Mechanisms underlying the resistance of acute lymphoblastic leukemia (ALL) blasts to l-
asparaginase are still incompletely known. Here we demonstrate that human primary bone …

Bone marrow niche is a major contributing factor in leukemia development and drug
resistance in acute myeloid leukemia (AML) patients. Although mimicking leukemic bone …

Mesenchymal stem/stromal cells (MSCs) are known as the issue in biology because of some
unpredictable characteristics in the different microenvironments especially in their bone …

Leukemic cell growth in the bone marrow (BM) induces a very stressful condition.
Mesenchymal stem cells (MSC), a key component of this BM niche, are affected in several …

Disease recurrence following cancer therapy remains an intractable clinical problem and
represents a major impediment to reducing the mortality attributable to malignant tumors …

The tumor microenvironment (TME) not only plays a pivotal role during cancer progression
and metastasis, but also has profound effects on therapeutic efficacy. Stromal cells of the …